• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估新发现的尿液生物标志物HIST1H4K对保加利亚前列腺癌患者诊断和预后的临床价值。

Evaluation of the clinical value of the newly identified urine biomarker HIST1H4K for diagnosis and prognosis of prostate cancer in Bulgarian patients.

作者信息

Kachakova D, Mitkova A, Popov E, Beltcheva O, Vlahova A, Dikov T, Hristova S, Mitev V, Slavov C, Kaneva R

机构信息

Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University-Sofia, Sofia, Bulgaria.

出版信息

J BUON. 2013 Jul-Sep;18(3):660-8.

PMID:24065480
Abstract

PURPOSE

Searching for diagnostic and prognostic biomarkers for prostate cancer (PC) is main public health priority. DNA methylation in body fluids is a stable, easily detectable and promising PC biomarker. The major advantages of urine-based assays are their noninvasive nature and the ability to monitor PC with heterogeneous foci. The aim of this study was to determine the diagnostic value of the recently identified candidate PC biomarker HIST1H4K.

METHODS

We investigated DNA methylation of HIST1H4K in urine samples from 57 PC patients, 29 controls with benign prostatic hyperplasia (BPH) and 50 young asymptomatic men (YAM) by MethyLight real-time PCR.

RESULTS

The frequency of HIST1H4K promoter hypermethylation significantly discriminated PC patients from YAM (AUC =0.763; 95% CI 0.672-0.839; p<0.0001), but did not show any statistical difference between PC patients and BPH controls (AUC=0.513, 95% CI 0.402-0.622; p=0.8255). HIST1H4K could not outperform the prostatic specific antigen (PSA) in our sample (AUC=0.785; 95% CI 0.679-0.870; p<0.0001). Methylation of HIST1H4K showed significant correlation with aging (r=0.5418; p<0.0001), but with no other clinicopathological characteristics.

CONCLUSION

The results suggest that the promoter hypermethylation of HIST1H4K is rather due to aging than related to prostate carcinogenesis. To elucidate this observation analysis of larger samples is needed.

摘要

目的

寻找前列腺癌(PC)的诊断和预后生物标志物是主要的公共卫生优先事项。体液中的DNA甲基化是一种稳定、易于检测且有前景的PC生物标志物。基于尿液检测的主要优点是其非侵入性以及能够监测具有异质性病灶的PC。本研究的目的是确定最近鉴定出的候选PC生物标志物HIST1H4K的诊断价值。

方法

我们通过甲基化荧光定量实时PCR研究了57例PC患者、29例良性前列腺增生(BPH)对照患者和50例年轻无症状男性(YAM)尿液样本中HIST1H4K的DNA甲基化情况。

结果

HIST1H4K启动子高甲基化频率显著区分了PC患者与YAM(曲线下面积[AUC]=0.763;95%置信区间[CI]0.672 - 0.839;p<0.0001),但在PC患者和BPH对照之间未显示出任何统计学差异(AUC=0.513,95% CI 0.402 - 0.622;p=0.8255)。在我们的样本中,HIST1H4K的表现不如前列腺特异性抗原(PSA)(AUC=0.785;95% CI 0.679 - 0.870;p<0.0001)。HIST1H4K的甲基化与衰老显著相关(r=0.5418;p<0.0001),但与其他临床病理特征无关。

结论

结果表明,HIST1H4K启动子高甲基化更多是由于衰老而非与前列腺癌发生相关。需要对更大样本进行分析以阐明这一观察结果。

相似文献

1
Evaluation of the clinical value of the newly identified urine biomarker HIST1H4K for diagnosis and prognosis of prostate cancer in Bulgarian patients.评估新发现的尿液生物标志物HIST1H4K对保加利亚前列腺癌患者诊断和预后的临床价值。
J BUON. 2013 Jul-Sep;18(3):660-8.
2
DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection.前列腺癌的DNA甲基化生物标志物:候选物的确认及尿液是用于非侵入性检测的最敏感体液的证据
Prostate. 2009 Sep 1;69(12):1257-69. doi: 10.1002/pros.20967.
3
GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?GSTP1基因高甲基化作为前列腺癌诊断的分子标志物:与临床分期、Gleason分级、前列腺特异抗原(PSA)值或年龄是否存在相关性?
Eur J Med Res. 2004 Nov 29;9(11):523-7.
4
DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.用于预测局限性前列腺癌根治术后生化复发的 DNA 甲基化特征。
J Clin Oncol. 2013 Sep 10;31(26):3250-8. doi: 10.1200/JCO.2012.47.1847. Epub 2013 Aug 5.
5
Multigene methylation analysis for detection and staging of prostate cancer.用于前列腺癌检测和分期的多基因甲基化分析
Clin Cancer Res. 2005 Sep 15;11(18):6582-8. doi: 10.1158/1078-0432.CCR-05-0658.
6
Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids.用于基于DNA检测体液中前列腺癌的荧光甲基化特异性聚合酶链反应
Cancer Res. 2000 Nov 1;60(21):5941-5.
7
I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma.前列腺腺癌中GSTP1基因的I105V多态性与启动子甲基化
Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):445-50.
8
Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.骨桥蛋白 mRNA 剪接变异体在前列腺癌和良性前列腺增生中的表达分析。
Exp Mol Pathol. 2012 Feb;92(1):13-9. doi: 10.1016/j.yexmp.2011.09.014. Epub 2011 Sep 22.
9
[Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].[血清与尿液前列腺特异性抗原比值:在血清前列腺特异性抗原水平为4至10 ng/ml时其在前列腺癌与腺瘤鉴别中的价值]
Chirurgie. 1997;122(8-9):478-82.
10
Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.谷胱甘肽S-转移酶P1(GSTP1)基因侧翼启动子区域CpG岛的高甲基化是检测前列腺癌的一种潜在血浆DNA生物标志物。
Cancer Detect Prev. 2007;31(1):59-63. doi: 10.1016/j.cdp.2006.11.001. Epub 2007 Feb 8.

引用本文的文献

1
CircRNA-3302 promotes endothelial-to-mesenchymal transition via sponging miR-135b-5p to enhance KIT expression in Kawasaki disease.环状RNA-3302通过吸附miR-135b-5p促进内皮-间充质转化,增强川崎病中KIT的表达。
Cell Death Discov. 2022 Jun 29;8(1):299. doi: 10.1038/s41420-022-01092-4.
2
Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review.区分良性前列腺增生与前列腺癌的生物标志物:文献综述
Cancer Manag Res. 2020 Jul 1;12:5225-5241. doi: 10.2147/CMAR.S250829. eCollection 2020.
3
Research status and progress of the RNA or protein biomarkers for prostate cancer.
前列腺癌RNA或蛋白质生物标志物的研究现状与进展
Onco Targets Ther. 2019 Mar 22;12:2123-2136. doi: 10.2147/OTT.S194138. eCollection 2019.